DrugCentral 2023 extends human clinical data and integrates veterinary drugs.
DrugCentral 2023 extends human clinical data and integrates veterinary drugs.
复制标题
DOI：
10.1093/nar/gkac1085
复制
发表时间：
2023-01-06
影响因子：
14.9
通讯作者：
Oprea, Tudor, I
中科院分区：
文献类型：
--
作者：
Avram, Sorin;Wilson, Thomas B.;Curpan, Ramona;Halip, Liliana;Borota, Ana;Bora, Alina;Bologa, Cristian G.;Holmes, Jayme;Knockel, Jeffrey;Yang, Jeremy J.;Oprea, Tudor, I
DrugCentral监控新药批准并审查药物信息。目前的更新包含285种药物（131种供人使用）。新增内容包括：（i）整合兽药（154种仅限动物使用），（ii）增加66种记录在案的标签外使用，以及（iii）从儿科和老年患者的药物警戒数据中识别药物不良事件。其他增强功能包括使用SMILES和基于UniProt登录码的“目标卡”进行化学结构搜索。利益统计数据包括：（一）60%的受保药物是专利和专有权过期的上市药物，17%是非上市药物，23%是专利和专有权有效的上市药物;（二）59%的药物是口服药物，33%是注射药物，18%是局部药物，按有效成分计算;（iii）在所有药物中，只有3%只供动物使用;但61%的兽药亦获准供人类使用;（iv）狗、猫及马是最具代表性的兽药目标物种;（v）动物药物的物理化学性质与人类药物非常相似。使用案例包括azaperone，唯一批准用于猪的镇静剂，以及ruxolitinib，Janus激酶抑制剂。
DrugCentral monitors new drug approvals and standardizes drug information. The current update contains 285 drugs (131 for human use). New additions include: (i) the integration of veterinary drugs (154 for animal use only), (ii) the addition of 66 documented off-label uses and iii) the identification of adverse drug events from pharmacovigilance data for pediatric and geriatric patients. Additional enhancements include chemical substructure searching using SMILES and ‘Target Cards’ based on UniProt accession codes. Statistics of interests include the following: (i) 60% of the covered drugs are on-market drugs with expired patent and exclusivity coverage, 17% are off-market, and 23% are on-market drugs with active patents and exclusivity coverage; (ii) 59% of the drugs are oral, 33% are parenteral and 18% topical, at the level of the active ingredients; (iii) only 3% of all drugs are for animal use only; however, 61% of the veterinary drugs are also approved for human use; (iv) dogs, cats and horses are by far the most represented target species for veterinary drugs; (v) the physicochemical property profile of animal drugs is very similar to that of human drugs. Use cases include azaperone, the only sedative approved for swine, and ruxolitinib, a Janus kinase inhibitor.
登录
查看更多内容
影响因子：
14.9
作者：
Avram S;Bologa CG;Holmes J;Bocci G;Wilson TB;Nguyen DT;Curpan R;Halip L;Bora A;Yang JJ;Knockel J;Sirimulla S;Ursu O;Oprea TI
通讯作者：
Oprea TI
影响因子：
14.9
作者：
Nguyen DT;Mathias S;Bologa C;Brunak S;Fernandez N;Gaulton A;Hersey A;Holmes J;Jensen LJ;Karlsson A;Liu G;Ma'ayan A;Mandava G;Mani S;Mehta S;Overington J;Patel J;Rouillard AD;Schürer S;Sheils T;Simeonov A;Sklar LA;Southall N;Ursu O;Vidovic D;Waller A;Yang J;Jadhav A;Oprea TI;Guha R
通讯作者：
Guha R
影响因子：
5.6
作者：
Huarte E;Peel MT;Verbist K;Fay BL;Bassett R;Albeituni S;Nichols KE;Smith PA
通讯作者：
Smith PA
影响因子：
12.3
作者：
Havrilla JM;Liu C;Dong X;Weng C;Wang K
通讯作者：
Wang K
专利外药物重新定位
影响因子：
5.6
作者：
Avram, Sorin;Curpan, Ramona;Oprea, Tudor, I
通讯作者：
Oprea, Tudor, I